DRAXIS Commences Marketing for Mysoline to Treat Epileptic Seizures Third Product of Eight Drugs In-licensed from Elan.Business Editors MISSISSAUGA, Ontario--(BUSINESS WIRE)--Feb. 29, 2000 (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :DRAX) (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :DAX.) DRAXIS Health Inc. (TSE:DAX)(NASDAQ:DRAX) today announced that it has now taken over the marketing and selling of Mysoline(R) in Canada. Mysoline(R) (primidone), an anti-convulsant drug for the treatment of epilepsy and seizure disorders, has been available in Canada for a number of years and is the third of eight drugs in-licensed from Elan. Dr. Martin Barkin, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of DRAXIS Health stated, "We are pleased that Mysoline(R) is now available through DRAXIS' Canadian pharmaceuticals division. DRAXIS Pharmaceutica continues to strengthen its product line-up and now markets drugs for the treatment of symptoms associated with Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. , sleep disorders, multiple sclerosis, spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. , stroke and epilepsy." Epilepsy, a term used to describe a variety of seizure disorders, is one of the most common disorders of the central nervous system, affecting more than 300,000 Canadians. Characterized by the tendency to have recurrent seizures, epileptic epileptic /ep·i·lep·tic/ (ep?i-lep´tik) 1. pertaining to or affected with epilepsy. 2. a person affected with epilepsy. ep·i·lep·tic n. One who has epilepsy. attacks occur when the standard electrical balance in the brain is disturbed. When this occurs, the corresponding physical reaction to the increased electrical activity is the seizure. DRAXIS Pharmaceutica is the pharmaceutical division of DRAXIS Health Inc. and is responsible for overseeing clinical trials, regulatory approval, marketing, and sales of pharmaceutical products in Canada. Its current focus is in the areas of neurology and dermatology. Neurology products currently available through Pharmaceutica include Mysoline(R) and Diastat(R) for epilepsy, Permax(R), Novo-Selegiline(R) and Eldepryl(R) for Parkinson's disease, Alertec(R) for narcolepsy narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and recurring unwanted episodes of sleep ("sleep attacks"). People with narcolepsy may abruptly fall asleep at almost any time, including while talking, eating, or even walking. , and Zanaflex(R) for the treatment of spasticity spasticity /spas·tic·i·ty/ (spas-tis´i-te) the state of being spastic; see spastic (2). spas·tic·i·ty n. 1. A spastic state or condition. 2. Spastic paralysis. associated with conditions such as multiple sclerosis, stroke, spinal cord injury, cerebral palsy and traumatic brain injury Traumatic brain injury (TBI), traumatic injuries to the brain, also called intracranial injury, or simply head injury, occurs when a sudden trauma causes brain damage. TBI can result from a closed head injury or a penetrating head injury and is one of two subsets of acquired brain . Pharmaceutica's line of dermatology products includes SpectroJel(R), Canada's leading non-soap cleanser. DRAXIS Health Inc. is a diversified specialty pharmaceutical company operating in three niche markets: Radiopharmaceuticals (DRAXIMAGE), Canadian sales and marketing (DRAXIS Pharmaceutica) and Companion Animal Health (through its global alliance with Pfizer Inc.). DRAXIS supports its own as well as third party manufacturing requirements through its subsidiary, DRAXIS Pharma, located in Kirkland, Quebec. Except for historical information, this news release contains certain forward-looking statements that involve risk and uncertainties, which may cause actual results to differ materially from the statements made. Such factors include, but are not limited to, changing market conditions, clinical trial results, the establishment of new corporate alliances, the impact of competitive products and pricing, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time-to-time in the Company's filings with the US Securities and Exchange Commission and Canadian securities authorities. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion